Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 78

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Cortical dysplasia+1

Not recruiting

Study on the Safety and Effectiveness of Sirolimus for Treating Drug-Resistant Epilepsy in Children with Rare Brain Disorders Linked to mTOR Pathway Activation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Sirolimus
  • Sponsor:Instytut Pomnik Centrum Zdrowia Dziecka

Relapsing-remitting multiple sclerosis

Not recruiting

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Giant cell arteritis

Not recruiting

Study on the Effectiveness of Tocilizumab, Methylprednisolone, and Prednisone for Patients with Acute Anterior Ischemic Optic Neuropathy in Giant Cell Arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Centre Hospitalier National D'Ophtalmologie Quinze-Vingts

Multiple sclerosis

Not recruiting

Study on Masitinib for Treating Primary or Secondary Progressive Multiple Sclerosis in Patients Without Relapse

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib
  • Sponsor:Ab Science

Cognitive disorder+1

Not recruiting

Study on the Effects of Phenserine and Donepezil in Patients with Early or Mild Alzheimer's Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:(-)-Phenserine tartrate
  • Sponsor:Helse Stavanger HF

Partial seizures

Not recruiting

Study of Cenobamate for Children with Partial-Onset Seizures

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Cenobamate
  • Sponsor:Sk Life Science Inc.

Prader-Willi syndrome

Not recruiting

Long-Term Study on Oxytocin for Children with Prader-Willi Syndrome Up to Age 4

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Oxytocin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Secondary progressive multiple sclerosis

Not recruiting

Study on Cladribine for Treating Secondary Progressive Multiple Sclerosis in Patients with Recent Progression and No Recent Relapses

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Cladribine
  • Sponsor:Instytut Psychiatrii I Neurologii

Multifocal motor neuropathy

Not recruiting

Study on the Safety and Effects of DNTH103 for Adults with Multifocal Motor Neuropathy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Angelman's syndrome

Not recruiting

Study on the Effects of GTX-102 for Children with Angelman Syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Apazunersen
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Amyotrophic lateral sclerosis

Not recruiting

Study on the Safety and Effects of AMT-162 Gene Therapy for Adults with SOD1 ALS

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 ENCODING MIRNA AGAINST SOD1 MRNA
  • Sponsor:uniQure biopharma B.V.

Atrial fibrillation+5

Not recruiting

Study of Allopurinol to Reduce Cardiovascular Events in High-Risk Patients with Heart Disease and Long-COVID Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Agencja Badań Medycznych

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.